Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > My take so far...
View:
Post by scarlet1967 on Dec 09, 2024 10:25am

My take so far...

 

 

The inclusion criteria for part 3 was patients with high grade serous ovarian cancer which  is very metastatic often diagnosed when the cancer has already spread to outside ovaries. The CR by definition is disappearance of all target lesions. 

As for PR again the definition is at least 30 percent reduction...

Would the one patient with a complete resolution of a liver lesion be classified as a CR as the targeted cancer was ovarian cancer?

The more than 25 percent shrinkage of the tumour size seems to be just short of being classified as PR, It almost seems like they need to reveal more details so one can get better understanding of the results for instance which tumours had 25 percent shrinkage? What was the plasma concentration of free docetaxel?

Overall as it was mentioned those results are from a small number of patients that's why one can be optimistic about the outcome plus they seem to be more confident about further dose escalation with these shortened dosing  intervals due to a better safety profile of the drug this time round.

Now my guess is that they need to find that partner moving on with part 4 most likely as the RP2D was not mentioned in the PR and they are now talking about higher doses to find the MTD. Also I have the feeling that they haven't released all details yet. I think these results plus all the various previous data should be good  enough for further research/ allocation of resources. Note the participants have been heavily treated, up to 8 prior cancer treatment regimens!!

 

 

 

Comment by muslix1 on Dec 09, 2024 11:20am
last week we have a arrangement whit Ionis Pharmaceuticals for sale product... and why not Ionis invest in it to be a partener for the additinal phase!!!
Comment by Wino115 on Dec 09, 2024 1:30pm
I think Ionis is focused elsewhere and has a very lengthy pipeline and 5 existing drugs. Doesn't seem likely but who knows?    On these results, decent but not powered enough to reach any conclusions - just more data to add. It does look like they understand the safety issues better with lower dosage more frequently being tolerable.  Now, how high can you go is the open ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities